

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**CLARIFICATION ANNOUNCEMENT –
MAJOR TRANSACTION IN RELATION TO ACQUISITION OF 100 %
OF THE ISSUED SHARES IN THE TARGET COMPANIES
INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER
SPECIFIC MANDATE**

Reference is made to the announcement of China NT Pharma Group Company Limited (the “**Company**”) dated 28 April 2025 in relation to Acquisition of 100% of The Issued Shares In The Target Companies Involving The Issue Of Consideration Shares Under Specific Mandate (the “**Announcement**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company would like to clarify that the figures for financial information of the units in relation to the disclosure PRC Operating Company for the years ended 31 December 2023 and 31 December 2024 should be RMB, not thousands RMB (i.e. RMB’000) as disclosed in the Announcement. The correct information are set out below:

	For the year ended 31 December 2023 (unaudited) <i>RMB</i>	For the year ended 31 December 2024 (unaudited) <i>RMB</i>
Revenue	2,437,639	1,810,151
Loss before taxation	1,930,143	3,049,543
Loss after taxation	1,907,899	3,068,549
Net liabilities as at the year end	1,205,370	1,863,179

Save for the above clarification, all other information in the Announcement remains unchanged.

By order of the Board of Directors
China NT Pharma Group Company Limited
Mr. Ng Tit
Chairman

Hong Kong, 29 April 2025

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Director is Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Ng Ming Kwan and Dr. Zhao Yubiao.